ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT

ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT

Summary

An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratificati...

Description

An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratificati...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage